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Abstract: Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents 
a new option for the treatment of complicated intra-abdominal and complicated skin and skin 
structure infections. It displays favorable activity in vitro against the most common causative 
Gram-positive, Gram-negative and anaerobic pathogens. In addition, tigecycline demonstrates 
activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus, 
vancomycin-resistant enterococci, and organisms (such as Escherichia coli and Klebsiella 
pneumoniae) producing extended-spectrum beta-lactamases. Tigecycline lacks activity in vitro 
against Pseudomonas and Proteus spp. In randomized clinical trials, tigecycline administered 
intravenously twice daily has demonstrated effi cacy similar to comparators for a variety of 
complicated skin and skin structure and complicated intra-abdominal infections. The potential 
for signifi cant drug interactions with tigecycline appears to be minimal. Dosing adjustment is 
needed for patients with severe hepatic impairment. The predominant side effect associated 
with its use to date has been gastrointestinal intolerance (nausea and vomiting).
Keywords: tigecycline, intra-abdominal infections, complicated skin and skin structure 
infections
Introduction
Tigecycline, formerly GAR-936 (Tygacil®; Wyeth Pharmaceuticals, Inc., Philadelphia, 
PA, USA), is a glycylcycline antimicrobial currently approved by the Food and 
Drug Administration (FDA) for the treatment of complicated intra-abdominal 
infections (cIAIs) and complicated skin and skin structure infections (cSSSIs) (Wyeth 
Pharmaceuticals 2007b). In addition to its broad spectrum in vitro activity against 
Gram-positives, Gram-negatives and anerobes, tigecycline demonstrates activity in 
vitro against MRSA, VRE, and ESBL-producing organisms (Wyeth Pharmaceuticals 
2007b). Therefore, it has potential applications in the management of polymicrobial 
infections or those due to resistant organisms.
Two of the most prevalent bacterial infections in clinical practice are cSSSIs 
and cIAIs. For example, surgical site infections are estimated to occur 500,000 
times per year among the 27 million surgical procedures performed (CDCP 1997). 
Studies evaluating the impact of surgical site infections have demonstrated that these 
infections are consistently associated with an increase in healthcare costs, prolonged 
hospitalizations, and an increase in morbidity and mortality (Vegas et al 1993; Kirkland 
et al 1999). Specifi cally, one study, evaluating cSSSI following hip replacement 
surgeries, found a median increased length of stay of 32.5 days directly related to the 
cSSSI; additionally, the morbidity rate associated with the cSSSI was 14.3% (Monge 
et al 2006). Similarly, the incidence of cIAIs is also diffi cult to determine because of 
its inclusion of a broad range of diagnoses. Among these, complicated appendicitis 
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may occur in up to 30% of appendicitis cases (Cueto et al 
2006). Additionally, cIaIs account for considerable hospital 
cost (Solomkin, Mazuski et al 2003). Inappropriate treatment 
has been associated with both treatment failures as well 
as increased mortality (Solomkin, Mazuski et al 2003). 
For example, Sturkenboom et al (2005) found a clinical 
failure rate of 35.7% and a mortality rate of 10.7% among 
patients receiving initial inappropriate therapy with 
intraabdominal infections.
Effective management of both cIAIs and cSSSIs require 
the timely institution of appropriate antimicrobital therapy 
and, in select cases, surgical interventions (Solomkin, 
Mazuski et al 2003; Stevens et al 2005). However, increases 
in antibiotic resistance seen in bacteria commonly causing 
such infections has made selection of appropriate empiric 
therapy challenging (Bochicchio et al 2006; Moet et al 2007). 
Data recently published from a worldwide multi-center 
longitudinal antimicrobial resistance tracking program, the 
SENTRY Antimicrobial Surveillance Program, reported 
rates of methicillin-resistant Staphylococcus aureus (MRSA) 
causing skin and skin structure infections ranging from 22.8% 
in Europe to 35.9% in North America (Moet et al 2007). 
Isolation of vancomycin-resistant enterococci (VRE) ranged 
from 3.6% in Europe to 12.2% in North America. Furthermore, 
Gram-negative organisms have also demonstrated diminished 
susceptibility. For example, reported rates of multidrug-
resistant Pseudomonas aeruginosa and extended-spectrum 
beta-lactamase (ESBL) producing Klebsiella spp. were 3.2% 
and 11.3% in North America, and 24.7% and 48.0% in Latin 
America, respectively. ESBL-producing Escherichia coli 
rates ranged from 6.6% in North America to 15.1% in Latin 
America (Moet et al 2007).
Rates of resistant organisms isolated in patients with 
cIAIs are also increasing. In vitro susceptibilities for over 
7,000 E. coli isolates from patients with intra-abdominal 
infections varied according to geographic region (Bochicchio 
et al 2006). The rate of ESBL-producing E. coli worldwide 
was 8.9% from 2002–2004, with the highest rates in the 
Asia/Pacifi c region (16.6%) (Bochicchio et al 2006).
The purpose of this article is to review the in vitro activity, 
pharmacokinetics, pharmacodynamics and clinical effi cacy 
and safety of tigecycline for the treatment of cIAIs and cSSSIs. 
Tigecycline’s role in therapy will also be discussed.
Overview of tigecycline
Pharmacology
Tigecycline (C
29
H
39
N
5
O
8
) is the first of a new class of 
antimicrobials called glycylcyclines, which are related 
to the tetracycline class (Wyeth Pharmaceuticals 2007b). 
Although structurally similar to minocycline, it differs 
primarily by the presence of a side chain addition at position 9 
(Figure 1). Tigecycline possesses a similar mechanism of action 
to tetracyclines in that it binds to the bacterial 30S ribosomal 
subunit, thereby inhibiting bacterial protein synthesis (Bergeron 
et al 1996). However, the binding affi nity for tigecycline to this 
ribosomal site is approximately 5 times that of tetracyclines 
(Bergeron et al 1996). Tigecycline also demonstrates 70S 
ribosomal subunit binding, with up to 100-fold greater affi nity 
as compared with tetracycline (Olson et al 2006).
Resistance to the tetracycline class most frequently 
involves protection of the ribosome and/or effl ux pumps 
(Chopra et al 1992; Speer et al 1992; Bergeron et al 1996) 
Binding to the 30S ribosomal subunit is thought to prevent 
ribosomal protection (Rasmussen et al 1994; Tally et al 
1995; Projan 2000; Chopra et al 2001; Zhanel et al 2004). 
Effl ux pumps are responsible for expelling drug from the 
intracellular to extracellular space, thus preventing action 
of the drug and therefore causing resistance (Li et al 1995; 
Poole et al 1996; Kohler et al 1997; Aires et al 1999; Mine 
et al 1999; Westbrock-Wadman et al 1999; Dean et al 2003). 
In contrast to tetracyclines, tigecycline is not usually affected 
by effl ux pumps. However, tigecycline is susceptible to 
effl ux pumps of the “resistance nodulation division” (RND) 
which are common among P. aeruginosa (Projan 2000); 
OH
N
O OH O
NH2
O
OH
OH
H
NTigecycline
N
H
O
H
N
H3C
H3C
H3C
H
H3C CH3 H3C CH3
Figure 1 Chemical structure.
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tigecycline is a know substrate for the pumps, described as 
MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-
OprM (Dean et al 2003). While Acinetobacter baumannii is 
generally sensitive to tigecycline, it can possess 2 of these 
RND pumps. Therefore, although further study is needed, 
emerging resistance to tigecycline while on therapy may be 
a concern for this organism (Rice 2006). Tigecycline appears 
to be unaffected by other mechanisms of resistance, including 
enzyme target changes and target site modif ications. 
Production of beta-lactamases (including ESBLs) also do 
not infl uence tigecycline’s antimicrobial activity (Wyeth 
Pharmaceuticals 2007b).
Microbiology
The Clinical and Laboratory Standards Institute (CLSI) has 
set the tigecycline in vitro minimum inhibitory concentration 
(MIC) susceptibility breakpoints for Streptococcus spp. 
(excluding S. pneumoniae) and Enterococcus faecalis 
(vancomycin-susceptible organisms) at 0.25 µg/mL. MIC 
breakpoints to be considered susceptible to tigecycline for 
S. aureus (including both MSSA and MRSA) are 0.5 µg/mL, 
while Enterobacteriaceae and anaerobes are set at 2 µg/mL 
and 4 µg/mL, respectively (CLSI 2003a, 2003b, 2004, 2005; 
Wyeth Pharmaceuticals 2007b). The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) susceptibility 
breakpoint for Enterobacteriaceae however, is 1 µg/mL, 
and breakpoints have not been established for anaerobes 
(EUCAST Steering Committee 2006).
Tigecycline displays excellent in vitro activity against 
most Gram-positive organisms (Sader et al 2005). A recent 
study evaluating 26,474 bloodstream infection isolates 
from 6 different continents found 99.4% (n = 8765) of 
S. aureus isolates susceptible with an MIC
90
 = 0.5 µg/mL
(range of 0.016–1 µg/mL) (Sader et al 2005). In this same 
study, 92.7% (n = 3258) of Enterococcus spp. were consid-
ered sensitive to tigecycline, with an MIC
90
 of 0.25 µg/mL 
(range of 0.016–2 µg/mL). Over 97 % (n = 605) of 
S. pneumoniae and viridans group streptococci (n = 378) were 
also considered susceptible, with MIC
90
 of 0.12 µg/mL 
(range 0.12–1 µg/mL) and 0.12 µg/mL (range 0.12–
0.5 µg/mL), respectively (Sader et al 2005).
In general, tigecycline demonstrated activity against 
Gram-positive bacteria resistant to other classes of antibiotics. 
Susceptibility of S. aureus to tigecycline appears to be 
independent of oxacillin susceptibility (Sader et al 2005). 
In addition, a vancomycin-resistant S. aureus strain 
(VRSA) isolated at Hershey Medical Center demonstrated 
an MIC of 0.125 µg/mL to tigecycline (Bogdanovich et al 
2005). Tigecycline also has potent in vitro activity against 
quinolone-resistant S. pneumoniae, with a reported MIC of 
0.12 µg/mL (Garrison et al 2007). For vancomycin-resistant 
E. faecium (n = 77) and vancomycin-resistant E. faecalis 
(n = 11), the MIC
90
 were 0.06 µg/mL and 0.12 µg/mL, 
respectively with 100% susceptibility in both species 
(Hoban et al 2005).
Tigecycline has shown potent in vitro activity against 
most Gram-negative organisms, with the exception of 
Proteus (n = 320) and Pseudomonas spp. (n = 1,338) with 
MIC
90
 (and ranges) of 4 µg/mL (0.25–16 µg/mL) and 
32 µg/mL (0.008–32 µg/mL), respectively (Sader et al 
2005). E. coli (n = 3217) and Klebsiella spp. (n = 1,503) are 
also susceptible to tigecycline. The MIC
90
 (and ranges) of 
0.25 g/mL (0.03–4 µg/mL) and 1 µg/mL (0.06–8 µg/mL) 
have been reported for these organisms, respectively (Sader 
et al 2005). Tigecycline also demonstrates activity against 
ESBL-producing strains of these pathogens. MIC
90
 (range) 
values for 142 ESBL-producing E. coli isolates and 278 
ESBL-producing K. pneumoniae isolates were 1 µg/mL 
(0.25–2 µg/mL) and 2 µg/mL (0.25–8 µg/mL), respectively 
(Bouchillon et al 2005b). MICs ranging 0.03–8 µg/mL and 
an MIC
90
 of 1 µg/mL was reported in the largest published 
study of Acinetobacter spp. isolates (n = 851) to date (Waites 
et al 2006). While several other in vitro studies have reported 
a high percentage of Acinetobacter spp. susceptible MICs 
according to CLSI criteria, many of these organisms would be 
considered resistant if utilizing EUCAST criteria (Bouchillon 
et al 2005a, 2005b; Sader et al 2005; Waites et al 2006). 
Tigecycline also remains active against carbapenem-resistant 
A. baumannii and pan-resistant A. baumannii according 
to 2 recent case reports, although tigecycline-resistant 
A. baumanii has emerged clinically (Bogaerts et al 2006; 
Taccone et al 2006; Peleg et al 2007).
Anaerobic activity of tigecycline has been studied in 
several clinical trials in which the results are summarized 
in a study by Bradford et al (Bradford et al 2005). Results 
from these studies demonstrate tigecycline’s potent anaerobic 
activity against Clostidium perfringens, Propionibacterium 
acnes, and Bacteroides fragilis. MICs for these organisms 
were below the CLSI susceptibility breakpoint of 4 µg/mL 
(Bradford et al 2005). Table 1 describes further the in vitro 
susceptibilities of tigecycline.
Pharmacokinetics
Tigecycline exhibits linear kinetics following intravenous 
(IV) administration (Muralidharan, Micalizzi et al 2005). Data 
from 103 healthy adult volunteers who received tigecycline 
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Table 1  In vitro susceptibilities of select aerobic and anaerobic organisms to tigecyclinea
Organism No. of  MIC90b MIC  %  References
 isolates  rangeb Susceptiblec 
Staphylococcus aureus 8765 0.5 0.016–1 99.4 (Sader et al 2005)
 MSSA 813 0.12 0.015–0.5 100 (Waites et al 2006)
 MRSA 879 0.25 0.03–0.5 100 (Waites et al 2006)
 VISA 19 0.5 0.06–1 NAd (Petersen et al 2002)
Staphylococci, coagulase- 3570 0.5 0.016–2 97.5 (Sader et al 2005)
negative (CoNS)     
CoNS, methicillin  71 0.5 0.03–1 NAd (Fritsche, Sader et al 2005)
susceptible     
CoNS, methicillin resistant 189 0.5 0.12–2 NAd (Fritsche, Sader et al 2005)
S. pneumoniae 605 0.12 0.12–1 --e (Sader et al 2005)
 S. pneumoniae, penicillin  279 0.5 NAd NAd (Hoban et al 2005)
 susceptible     
 S. pneumoniae, penicillin- 54 0.25 NAd NAd (Hoban et al 2005)
 resistant     
Streptococci, β-hemolytic 769 0.12 0.12–0.5 99.7 (Sader et al 2005)
Streptococci, viridans  378 0.12 0.12–0.05 98.1 (Sader et al 2005)
group     
Enterococci spp. 3258 0.25 0.016–2 92.7 (Sader et al 2005)
 Enterococcus spp.- 466 0.5 0.12–1 NAd (Fritsche, Sader et al 2005)
 vancomycin susceptible     
 Enterococcus spp.- 39 0.25 0.03–0.5 NAd (Fritsche, Sader et al 2005)
 vancomycin resistant     
Nocardia spp. 51 4 0.06–8 NAd (Cercenado et al 2007)
Escherichia coli 3217 0.25 0.03–4 99.9 (Sader et al 2005)
 ESBL-producing E.coli 115 0.38 0.047–0.75 NAd (Sorlozano et al 2006)
Klebsiella pneumonia 1334 2 0.008–8 95 (Waites et al 2006)
 ESBL-producing  126 2 0.12–8 92.1 (Waites et al 2006)
K. pneumoniae     
Klebsiella oxytoca 248 1 0.06–4 98.8 (Waites et al 2006)
Enterobacter aerogenes 419 1 0.06–8 95.7 (Waites et al 2006)
Enterobacter cloacae 1089 2 0.008–8 93 (Waites et al 2006)
Haemophilus infl uenzae 336 0.25 NAd --e (Hoban et al 2005)
 H. infl uenzae, β-lactamase  93 0.25 NAd --e (Hoban et al 2005)
 positive     
Moraxella catarrhalis 54 0.5 NAd --e (Gales et al 2005)
Serratia marscens 658 1 0.012–8 97 (Waites et al 2006)
Citrobacter spp. 252 0.5 NAd 86.9 (Fritsche, Strabala et al 2005)
Acinetobacter baumannii 851 1 0.03-8 --e (Waites et al 2006)
Pseudomonas aeruginosa 1338 32 0.008–32 --e (Waites et al 2006)
Stenotrophomonas  203 2 0.12–8 --e (Sader et al 2005)
maltophilia     
Burkholderia cepacia 21 16 0.25–32 --e (Cheng et al 2005)
Campylobacter jejuni 108 4 0.12–16 --e (Rodriguez-Avial et al 2006)
Campylobacter coli 8 16 0.5–16 --e (Rodriguez-Avial et al 2006)
Proteus mirabilis 320 4 0.25–16 46.9 (Sader et al 2005)
Bacteroides fragilis 2721 8 0.06–32 94.9 (Snydman et al 2007)
Bacteroides fragilis group 5225 8 0.06–64 95.7 (Snydman et al 2007)
 B. distasonis 274 8 0.25–32 97.9 (Snydman et al 2007)
 B. ovatus 545 8 0.125–16 96.7 (Snydman et al 2007)
 B. thetaiotaomicron 978 8 0.25–32 96.4 (Snydman et al 2007)
 B. vulgatus 306 4 0.25–16 98.4 (Snydman et al 2007)
C. perfringens 51 1.0 0.06–2 NAd (Bradford et al 2005)
Clostridium diffi cile 12 0.06 0.06 NAd (Goldstein et al 2006)
Fusobacterium varium 13 0.25 0.06–0.25 NAd (Goldstein et al 2006)
Lactobacillus spp. 15 0.5 0.06–1 NAd (Goldstein et al 2006)
aAdapted with permission from (Townsend ML et al 2006.  Tigecycline:  a new glycylcycline antimicrobial. Int J Clin Pract, 60:1662–72. Blackwell Publishing.) bMIC = minimum 
inhibitory concentration. cAccording to CLSI criteria. dNA= not available. eNo CLSI criteria available.
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intravenously (100 mg followed by 50 mg every 12 hours over 
60 minutes) produced steady state maximum plasma concen-
trations (Cmax) and minimum plasma concentrations (Cmin) of 
0.63 µg/mL and 0.13 µg/mL, respectively. The area under the 
plasma concentration-time curve from 0 to 24 hours (AUC0–24) 
was 4.70 µg·h/mL (Muralidharan, Micalizzi, et al 2005; Wyeth 
Pharmaceuticals 2007b). Patients with cSSSIs (n = 81) partici-
pating in a phase II study demonstrated pharmacokinetic param-
eters similar to healthy adult volunteers, with a Cmax of 0.403 
µg/ml and AUC
0–12
 of 2.24 µg·h/mL (Postier et al 2004).
Tigecycline is highly protein bound (71%–89%) at 
plasma drug concentrations achieved in clinical trials 
(0.1–1.0 µg/mL) (Wyeth Pharmaceuticals 2007b). The 
volume of distribution of tigecycline reported from healthy 
volunteer studies is 7–10 L/kg (Muralidharan, Micalizzi et al 
2005). Based on animal and human studies, tigecycline can 
distribute into various bodily fl uids and tissues, such as the 
lungs, skin, peritoneal fl uid, gall bladder, colon, heart, liver, 
meninges and bone (Tombs 1999; Rodvold et al 2005; Conte 
et al 2005; Gotfried et al 2005; Sun et al 2005; Rodvold et al 
2006; Scheetz et al 2006; Wyeth Pharmaceuticals 2007b). In 
adults undergoing medical or surgical procedures (n = 104), 
serum, tissue, and body fl uid concentrations of tigecycline 
were evaluated following a single dose of 100 mg of 
tigecycline administered over 30 minutes (Rodvold et al 
2006). The mean ratio of tigecycline in the tissue to serum 
(expressed as AUC
0–24
) was 537 in the bile, 23 for the gall 
bladder, 2.6 for the colon, and 2.0 for the lung (Rodvold 
et al 2006). The highest concentration of tigecycline was 
found in the bile, which is consistent with the drug’s known 
route of elimination. Additionally, lower tissue to serum 
concentrations were achieved in the bone, synovial fl uid, and 
cerebrospinal fl uid (CSF). The mean ratio of tigecycline in the 
tissue to serum (expressed as AUC
0–24
) was 0.41 for the bone, 
0.31 for the synovial fl uid, and 0.11 for the CSF. The highest 
CSF to serum ratios occurred approximately 24 hours after 
infusion. Of note, bone penetration of tigecycline in animal 
models was higher than what was achieved in this human 
study (Tombs 1999; Rodvold et al 2006). The inconsistency 
of bone penetration in this study versus previous animal 
studies may have been due to poor extraction techniques, 
tight binding of the drug to bone, or the single dose design 
of the study. Additionally, peritoneal fl uid penetration of 
tigecycline has been reported in a critically ill patient. The 
extrapolated penetration into the peritoneal fl uid was about 
50% (Scheetz et al 2006). Tigecycline has also been shown 
to have a 74% (mean) penetration into cantharidin-induced 
blisters in healthy volunteers (n = 10) (Sun et al 2005).
Tigecycline is not extensively metabolized. The main 
metabolic pathway of tigecycline is glucuronidation. Non-
active metabolites that were recovered in the urine and feces 
include a glucuronide, its epimer (M1 and M2), and N-acetyl-
9-aminominocycline (M6) (Hoffmann et al 2004; Rello 2005; 
Wyeth Pharmaceuticals 2007b). The pharmacokinetic model 
of tigecycline follows a 2-compartment model with fi rst-
order elimination based on pooled data from Phase II and III 
studies involving patients with cSSSIs and cIAIs (Van Wart 
et al 2006). The primary route of elimination of tigecycline 
is through feces and the biliary tract (59%) as unchanged 
drug and metabolites. Secondary routes of elimination 
include glucuronidation and renal excretion (33%). Renal 
excretion only accounts for about 10%–15% of the systemic 
clearance of tigecycline (Hoffmann et al 2004; Muralidharan, 
Micalizzi et al 2005). The terminal half-life of tigecycline 
is 37–67 hours and the total systemic clearance is 0.2–0.3 
L/h/kg (Muralidharan, Micalizzi et al 2005).
Pharmacodynamics
Tigecycline demonstrates time-dependent bacteriostatic 
activity in vitro (van Ogtrop et al 2000; Reese et al 2005). Its 
post-antibiotic effect against Gram-negative organisms ranges 
from 2 to 5 hours, and 8.9 hours for S. pneumoniae (van Ogtrop 
et al 2000; Reese et al 2005). Recent animal and clinical data 
suggests the area-under-the concentration-time curve (AUC) 
to MIC ratio (AUC/MIC) may be a reliable predictor for 
effi cacy with tigecycline (Meagher et al 2005; Garrison et al 
2007; Meagher et al 2007). The AUC/MIC ratios described 
in the literature for in vitro activity range from 79–158 
when evaluating quinolone-resistant S. pneumoniae, MRSA 
and VRE (Garrison et al 2007). In a study by Meagher and 
colleagues (Meagher et al 2007), cSSSI patients with S.aureus 
and streptococci as the primary organisms were evaluated to 
determine the pharmacodynamic properties of tigecycline. 
Based on the results of this study, the AUC/MIC ratio of 17.9 
or higher was a signifi cant predictor of both microbiological 
and clinical response in cSSSI patients (Meagher et al 
2007). Although the AUC/MIC ratios range in the literature 
depending on the organism and infection, no consensus to date 
has been reached to determine the ideal AUC/MIC ratio for 
particular disease states.
Special populations
Tigecycline’s pharmacokinetic profi le appears to be inde-
pendent of age, ethnic backgrounds (African-American, 
Hispanic, Asian, and Caucasian), and gender. (Meagher 
et al 2005; Muralidharan, Fruncillo et al 2005). Patients with 
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renal impairment (creatinine clearance of 30 mL/min or 
hemodialysis-dependent) had a non-signifi cant increase in 
C
max
 and AUC in comparison to healthy volunteers (Troy 
et al 2003). Additionally, tigecycline was not found to be 
signifi cantly removed via hemodialysis. Therefore, no dosing 
adjustments are necessary in patients with renal dysfunction 
or who are hemodialysis dependent (Troy et al 2003; Wyeth 
Pharmaceuticals 2007b). In contrast to patients with renal dys-
function, patients with severe hepatic impairment (ie, Child-
Pugh Class C) had a 43% increase in tigecycline’s half-life and 
a 55% reduction in drug clearance (Saunders et al 2005). Thus, 
it is recommended in these patients that the maintenance dose 
of tigecycline be reduced to 25 mg every 12 hours in patients 
with severe hepatic insuffi ciency (Wyeth Pharmaceuticals 
2007b). No adjustments are needed for patients with mild 
to moderate hepatic impairment (Child-Pugh Class A or B) 
(Wyeth Pharmaceuticals 2007b). Pharmacokinetic studies 
are currently lacking in obese/low-body-weight individuals, 
the pediatric population, and patients who are lactating 
or pregnant.
Drug interactions
To date, no signifi cant drug-drug interactions have been 
reported with tigecycline. Tigecycline is not metabolized 
by the cytochrome P450 system and as a result, it does not 
alter the metabolism of drugs that go through this system 
nor do these drugs affect the concentration of tigecycline 
(Wyeth Pharmaceuticals 2007b). Studies evaluating the 
concurrent administration of tigecycline with either digoxin 
or warfarin in healthy adults have not demonstrated a 
signifi cant drug-drug interaction between tigecycline and 
either of these drugs (Zimmerman et al 2004; Raible et al 
2005; Wyeth Pharmaceuticals 2007b; Zimmerman et al 
2007). However, the manufacturer of tigecycline does 
recommend that the international normalized ratio (INR) 
as well as signs and symptoms of bleeding be routinely 
assessed when tigecycline is administered with warfarin 
(Wyeth Pharmaceuticals 2007b).
Safety and tolerability
Overall, tigecycline was well-tolerated in phase III clinical 
studies with only 5% of patients discontinuing therapy due 
to adverse events in comparison to 4.7% in the comparator 
arms (vancomycin-aztreonam 5.3% and imipenem-cilastatin 
4.4%) (Babinchak et al 2005; Ellis-Grosse, Babinchak et al 
2005; Wyeth Pharmaceuticals 2007b).
The most common adverse events associated with the 
administration of tigecycline in phase II and III studies was 
mild to moderate nausea and vomiting. This occurred most 
often during the fi rst 2 days of drug therapy, and was the most 
common reason for discontinuing drug therapy (Postier et al 
2004; Oliva et al 2005; Babinchak et al 2005; Breedt et al 
2005; Fomin et al 2005; Muralidharan, Fruncillo et al 2005; 
Muralidharan, Micalizzi et al 2005; Sacchidanand et al 2005; 
Wyeth Pharmaceuticals 2007b). The incidence of nausea was 
34.5% (versus 8.2% in vancomycin-aztreonam; p  0.001) 
in the cSSSIs studies and 24.4% (versus 19% in imipenem-
cilastatin; p = 0.01) in the cIAIs studies. The incidence of 
vomiting was 19.6% (versus 3.6% in vancomycin-aztreonam; 
p  0.001) and 19.2% (versus 14.3% in imipenem-cilastatin; 
p = 0.008) in cSSSIs and cIAIs studies, respectively (Oliva 
et al 2005; Babinchak et al 2005; Fomin et al 2005; Breedt 
et al 2005; Ellis-Grosse, Babinchak et al 2005). The exact 
mechanism of tigecycline-induced nausea and vomiting 
remains unknown, but it is not related to the release of sero-
tonin in the gastrointestinal tract (Muralidharan, Micalizzi et al 
2005). Nausea and vomiting has occurred more frequently at 
higher doses and in patients 50 years of age, female, and 
non-European descent (Muralidharan, Fruncillo et al 2005; 
Wyeth Pharmaceuticals 2007b). While coadministration of 
food may potentially improve the tolerability of tigecycline, 
altering the rate of infusion has not been successful in deceas-
ing the incidence of nausea and vomiting (Muralidharan, 
Micalizzi et al 2005). Likewise, administration of antiemetics 
(such as prochlorperazine, ondansetron, or metoclopramide) 
does not signifi cantly alter the incidence of nausea and vomit-
ing (Muralidharan, Micalizzi et al 2005; Wyeth Pharmaceu-
ticals 2007b). During phase III clinical studies, diarrhea was 
reported in 12.7% of patients receiving tigecycline (Wyeth 
Pharmaceuticals 2007b). However, there were no published 
cases of Clostridium diffi cile associated diarrhea in these clini-
cal studies (Babinchak et al 2005; Ellis-Grosse, Babinchak 
et al 2005; Wyeth Pharmaceuticals 2007b).
Tigecycline’s ability to induce C. diffi cile infections has 
also been evaluated (Baines et al 2006). In a human gut model 
involving 2 epidemic strains of C. diffi cile, the gut fl ora was 
signifi cantly decreased although the C. diffi cile spores did 
not “proliferate”; in addition, cytotoxin was not produced 
(Baines et al 2006). This seems to correlate clinically, as only 
limited cases of C. diffi cile infections have been reported with 
tigecycline to date (Wyeth Pharmaceuticals 2007a). However, 
as with all antimicrobials, tigecycline can theoretically 
predispose a patient to a C. diffi cile infection.
Due to the structural similarities between tetracyclines 
and tigecycline, cross-reactivity may occur between these two 
classes of drugs, and caution should be used in patients with 
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known hypersensitivity reactions to tetracyclines (Zhanel 
et al 2004; Wyeth Pharmaceuticals 2007b). Furthermore, 
similar side effects may exist between tetracyclines and 
tigecycline such as photosensitivity reactions, pancreatitis, 
and tooth discoloration in children under 8 years old (Zhanel 
et al 2004; Wyeth Pharmaceuticals 2007b). Long-term safety 
has not been published with the use of tigecycline to date.
Clinical effi cacy
Complicated intra-abdominal infections
As with any type of infection, the objectives for the treatment 
of cIAI are to minimize the time to clinical improvement, pre-
vent recurrence, and eradicate the causative microorganisms. 
As with most infections, healthcare-associated infectious 
diseases generally require broader antibacterial coverage for 
such resistant organisms as P. aerunginosa, Enterobacter 
spp. and MRSA as compared with community-associated 
infections (Solomkin, Mazuski et al 2003).
Guidelines published by the Infectious Diseases Society 
of America for the treatment of cIAIs describe the use of a 
single-agent, broad-spectrum antimicrobial agent or the use 
of a combination of antibiotics with activity against common 
enteric fl ora (Solomkin, Mazuski et al 2003). They summarize 
data from numerous trials. For example, monotherapy for 
the treatment of cIAIs studied in randomized, prospective 
clinical trials include the β-lactam/β-lactamase inhibitors 
such as ampicillin/sulbactam, piperacillin/tazobactam, and 
ticarcillin/clavulanic acid (Eklund et al 1993; Walker et al 
1993; Dougherty et al 1995; Jaccard et al 1998; Allo et al 
1999; Ohlin et al 1999; Cohn et al 2000). The carbapenems 
(ertapenem, imipenem/cilastatin and meropenem) as well as 
certain cephalosporins (ceftotetan and cefoxitin) have also 
been studied (Poenaru et al 1990; Brismar et al 1992; Eklund 
et al 1993; Brismar et al 1995; Condon et al 1995; Geroulanos 
1995; Huizinga et al 1995; Angeras et al 1996; Berne et al 
1996; Christou et al 1996; Colardyn et al 1996; Solomkin 
et al 1996; Barie et al 1997; Basoli et al 1997; Donahue 
et al 1998; Allo et al 1999; Solomkin et al 2001; Solomkin, 
Mazuski et al 2003; Solomkin, Yellin et al 2003). As for com-
bination regimens, aminoglycosides, quinolones or certain 
cephalosporin agents in addition to anti-anaerobic medications 
(clindamycin or metronidazole) also have data to support their 
use (Solomkin, Mazuski et al 2003).
Tigecycline has been studied specifi cally in adult patients 
with cIAIs in 2 phase III, noninferiority, multicenter, 
randomized, double-blind trials (Oliva et al 2005; Fomin 
et al 2005) and are presented together in a pooled analysis 
(Babinchak et al 2005). Patients 18 years old and older who 
also required surgical intervention for treatment of cIAIs were 
included. The cIAIs were defi ned as perforated intestines, 
intra-abdominal abscesses, appendicitis, diverticulitis, or 
cholecysitis with perforation and/or abscess with fecal 
contamination, or perforated gastric/duodenal ulcers, and 
complicated peritonitis (Babinchak et al 2005). Patients were 
stratifi ed by randomization according to their APACHE II 
scores and received either intravenous tigecycline 100 mg 
followed by 50 mg every 12 hours or intravenous imipenem-
cilastatin 500 mg every 6 hours (adjusted based on the 
patient’s weight and renal function). Patients were generally 
treated for 5–14 days.
The primary endpoint for these studies was “the clinical 
response at the test-of-cure visit (12–42 days after therapy) 
in the co-primary end point microbiologically evaluable 
[ME] and microbiological modifi ed intent-to-treat [mm-ITT] 
populations” (Babinchak et al 2005).
A total of 1658 patients were randomized in these 
2 trials; the mm-ITT population included 1262 patients, 
and the ME population was composed of 1025 patients. The 
mean of subject age was 47 years, and the most commonly 
reported intra-abdominal infection was complicated appen-
dicitis (50.6%, tigecycline and 48.7%, imipenem-cilastatin) 
followed by complicated cholecystitis (12.8%, tigecycline 
and 15.1%, imipenem-cilastatin). The average APACHE 
II score was 6.3 (tigecycline group) and 6 (imipenem-
cilastatin) with only 35 patients having an APACHE II score 
15. The mean duration of therapy with either agent was 
approximately 8 days (Babinchak et al 2005). Clinical cures 
were reported in 80.2% (506/631) and 81.5% (514/631) of 
tigecycline and imipenem m-mITT groups, respectively 
(% difference (95%CI): −1.3% (–5.8% to 3.2%)). The ME 
population had similar response rates, with 86.1% (441/512) 
and 86.2% (442/513) clinical cure rate in the tigecycline and 
imipenem-cilastatin groups, respectively (Babinchak et al 
2005). Although many organisms were identifi ed, the most 
commonly isolated organisms included E. coli (n = 665), 
S. anginosus (n = 198), K. pneumonia (n = 112) and B. fragilis 
(n = 160) (Babinchak et al 2005). The most commonly 
reported adverse events reported in these studies included 
gastrointestinal complaints with a statistically higher rate in 
the tigecycline group compared with those receiving imi-
penem-cilastatin. There were a total of 44.4% and 39.4% 
of reported adverse events with the digestive system in the 
tigecycline and imipenem-cilastatin patients, respectively 
(p = 0.04) (Babinchak et al 2005).
Based on the results of this analysis, tigecycline appears to 
be as safe and effective as imipenem in cIAIs. One limitation 
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in this trial was the relatively few resistant organisms isolated. 
Thus, these studies may not apply to the patient population 
in which resistance is a concern. Additional clinical trials 
examining tigecycline’s use in cIAIs including resistant 
organisms will further the utility of tigecycline in this type 
of infection.
Complicated skin and skin structure 
infections
Complicated skin and skin structure infections (cSSSIs) either 
involve deep soft tissues or require surgical debridement 
or interventions. These infections often require parenteral 
antimicrobial treatment and frequently occur in patients with 
other comorbid disease states (such as diabetes or peripheral 
vascular disease) in which their response to antimicrobial 
treatment can be suboptimal. Examples of cSSSIs include 
major abscesses, burns, surgical site infections, diabetic 
foot, and infected ulcers (CDER 1998; Nichols 1999, 2001; 
Dinubile et al 2004; Lee et al 2005).
Numerous pathogens have been associated with cSSSIs 
and are often dependent upon the patient and clinical sce-
nario. In general though, S. aureus and Streptococcus spp. 
tend to be the predominant pathogens with Gram-negatives, 
anaerobes, and resistant pathogens such as MRSA becoming 
more of a factor in immunocompromised patients, injection 
drug users, and nosocomially-acquired infections (Rennie 
et al 2003; Dinubile et al 2004). Additionally, some infec-
tions (such as lower extremity infections in diabetic patients) 
tend to be more polymicrobial in nature (Doern et al 1999; 
Rennie et al 2003; Dinubile et al 2004).
Besides surgical debridement, there are multiple antimi-
crobial options that are available for the treatment of cSSSIs. 
Empiric antimicrobial therapy should include coverage for 
Gram-positive cocci such as staphlococci and streptococci. 
Additional coverage for Gram-negative organisms, anaer-
obes (such as B. fragilis group), or resistant pathogens is 
dependent upon patient risk factors for such organisms 
(Nichols 1999; Dinubile et al 2004; Stevens et al 2005; Lee 
et al 2005). Local resistance patterns should also play an 
important role in deciding appropriate empiric treatment. 
According to the skin and soft tissue infections guidelines 
set forth by the Infectious Diseases Society of America (Fass 
et al 1985; Tan et al 1993; Talan et al 2000; Grayson et al 
2002; Graham, Lucasti et al 2002; Graham, Talan et al 2002; 
Stevens et al 2005; Fabian et al 2005; Giordano et al 2005), 
treatment options include broad-spectrum antibiotics such 
as carbapenems (eg, imipenem/cilastin, meropenem, ertap-
enem), beta-lactam/beta-lactamase inhibitor combinations 
(eg, piperacillin-tazobactam, ticarcillin-clavulanate,
ampicillin-sulbactam), cephalosporins (eg, cefazolin, cefoxi-
tin), and fl uoroquinolones (eg, levofl oxacin, moxifl oxacin) 
used alone or in combination with clindamycin or metroni-
dazole for anerobic coverage. The addition of vancomycin or 
other newer antimicrobial agents (eg, daptomycin, linezolid, 
quinupristin/dalfopristin, tigecycline) with activity against 
resistant organisms such as MRSA, VRE, and ESBL-
producing gram negative organisms is dependent upon the 
clinical circumstances of the patient (Nichols et al 1999; 
Stevens et al 2000; Stevens et al 2005; Lipsky et al 2005).
Tigecycline has been evaluated for the treatment of cSSSIs 
in two randomized, multi-centered, double-blind phase 3 
studies (Breedt et al 2005; Ellis-Grosse, Babinchak et al 2005; 
Sacchidanand et al 2005). In both studies, hospitalized adult 
patients with cSSSIs (defi ned as deep soft tissue infections, 
soft tissue infections requiring surgical debridement, or soft 
tissue infections in patients with underlying disease such as 
diabetes or peripheral vascular disease) were randomized (1:1) 
to receive either tigecycline (100 mg loading dose followed 
by 50 mg every 12 hours over 60 minutes) or vancomycin 
(1 g every 12 hours over 60 minutes with adjustments based 
on renal function) plus aztreonam (2 g every 12 hours over 
60 minutes) intravenously for up to 14 days. At the discretion 
of the investigators, aztreonam therapy could be discontinued 
after 48 hours of treatment. The clinical response at the test-
of-cure-visit (12–92 days after the last dose) in the clinically 
evaluable (CE) and the clinical modifi ed intention-to-treat 
(c-mITT) was the primary endpoint of these studies (Ellis-
Grosse, Babinchak et al 2005).
Pooled analysis of the data (N = 1129) demonstrated that 
baseline demographics between each group was similar in 
terms of type of infection and incidence of other comorbid 
disease states (Ellis-Grosse, Babinchak et al 2005). Cauca-
sian (68.2%) men (62.1%) with a mean age of 48 made up 
the majority of the patients enrolled in the studies. Patients 
were on antibiotic treatment for a mean of 8 days in each 
group. The most common type of cSSSIs was cellulitis 
(59%). In the c-mITT analysis (comprised of patients who 
received at least 1 dose of the study drug and had clinical 
evidence of a cSSSI; ) (N = 1057), 79.7% in the tigecycline 
arm (429/538) versus 81.9% in the vancomycin-aztreonam 
arm (425/519) [95% CI for the difference –2.1 (–7.1% to 
2.8%)] had a clinical cure, defi ned as resolution of the signs 
and symptoms of cSSSI and completion of antibiotic therapy. 
Clinical cure rates for the CE population (defi ned as c-mITT 
population without P. aeruginosa as sole isolate, no other 
concurrent antibiotic therapy, and assessed for failure or cure 
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at the TOC visit) (N = 833) were 86.5% for patients receiving 
tigecycline (365/422) versus 88.6% in the comparator arm 
(364/411) [95% CI for the difference, –2.1 (–6.8 to 2.7)]. The 
most common organism isolated was MSSA (N = 254). Cure 
rates for MSSA were 88.8% (N = 119/134) versus 90.8% 
(N = 109/120), respectively for tigecycline and vancomycin-
aztreonam arms. Sixty-fi ve patients had MRSA isolates, of 
which 32% (N = 21/65) were considered to be community-
acquired strains. Overall cure rates for MRSA were 78.1% 
(N = 25/32) in the tigecycline arm and 75.8% (N = 25/33) 
for the vancomycin-aztreonam arm (Ellis-Grosse, Babinchak 
et al 2005). ESBL-producing organisms treated with tige-
cycline had clinical cure rates of 77.8% (N = 9) for E. coli, 
85.7% (N = 7) for K. pneumoniae, and 100% (N = 3) for 
P. mirabilis (Ellis-Grosse, Bradford et al 2005). The authors 
concluded from these pooled analysis, that tigecycline was 
noninferior to the combination of vancomycin-aztreonam 
in the treatment of cSSSIs. The incident of adverse events 
was similar between the groups (67.7% tigecycline versus 
61.1% vancomycin-aztreonam) with the most common 
adverse events being related to gastrointestinal complaints 
(46% tigecycline versus 21% vancomycin-aztreonam; p  
0.001) (Ellis-Grosse, Babinchak et al 2005).
Conclusions
Tigecycline represents a new treatment option for both 
cSSSIs and cIAIs due, in part, to its favorable in vitro 
activity against a wide variety of aerobic Gram-positive, 
Gram-negative and anaerobic organisms (including 
multidrug-resistant pathogens such as MRSA, VRE, 
and ESBL-producing strains of E. coli and Klebsiella). 
In contrast, tigecycline lacks activity in vitro against 
P. aeruginosa and P. mirabilis. Following twice daily 
intravenous administration, it is extensively distributed 
to various body tissues and fl uids. Dose modifi cation is 
required in patients with signifi cant hepatic impairment. 
Because of the metabolic profi le of tigecycline, the potential 
for drug interactions appears to be minimal.
Based on existing clinical effi cacy and safety data, tige-
cycline has been FDA-approved for use as monotherapy 
for the treatment of cSSSIs and cIAIs. Published clinical 
effi cacy data in humans reports tigecycline as noninferior 
to comparators for such indications. Tigecycline might be 
particularly useful in suspected or documented polymicro-
bial infections, including those patients otherwise requiring 
combination therapies due to the presence of drug-resistant 
pathogens such as MRSA, VRE, or ESBL-producing strains 
of E. coli and K. pneumoniae. In contrast, its role as part of 
combination therapy with other antimicrobials is uncertain. 
Gastrointestinal side effects (mainly nausea) may be prob-
lematic in some patients.
References
Aires JR, Kohler T, Nikaido H, et al. 1999. Involvement of an active effl ux 
system in the natural resistance of Pseudomonas aeruginosa to amino-
glycosides. Antimicrob Agents Chemother, 43:2624–8.
Allo MD, Bennion RS, Kathir K, et al. 1999. Ticarcillin/clavulanate versus 
imipenem/cilistatin for the treatment of infections associated with gan-
grenous and perforated appendicitis. Am Surg, 65:99–104.
Angeras MH, Darle N, Hamnstrom K, et al. 1996. A comparison of imipenem/
cilastatin with the combination of cefuroxime and metronidazole in the 
treatment of intra-abdominal infections. Scand J Infect Dis, 28:513–18.
Babinchak T, Ellis-Grosse E, Dartois N, et al. 2005. The effi cacy and 
safety of tigecycline for the treatment of complicated intra-abdominal 
infections: analysis of pooled clinical trial data. Clin Infect Dis, 41 
(Suppl 5):S354–67.
Baines SD, Saxton K, Freeman J, et al. 2006. Tigecycline does not induce 
proliferation or cytotoxin production by epidemic Clostridium diffi cile 
strains in a human gut model. J Antimicrob Chemother, 58:1062–5.
Barie PS, Vogel SB, Dellinger EP, et al. 1997. A randomized, double-
blind clinical trial comparing cefepime plus metronidazole with 
imipenem-cilastatin in the treatment of complicated intra-abdominal 
infections. Cefepime Intra-abdominal Infection Study Group. Arch 
Surg, 132:1294–302.
Basoli A, Meli EZ, Mazzocchi P, et al. 1997. Imipenem/cilastatin (1.5 g 
daily) versus meropenem (3.0 g daily) in patients with intra-abdominal 
infections: results of a prospective, randomized, multicentre trial. Scand 
J Infect Dis, 29:503–8.
Bergeron J, Ammirati M, Danley D, et al. 1996. Glycylcyclines bind to the 
high-affi nity tetracycline ribosomal binding site and evade Tet(M)- and 
Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother, 
40:2226–8.
Berne TV, Yellin AE, Appleman MD, et al. 1996. Meropenem versus tobra-
mycin with clindamycin in the antibiotic management of patients with 
advanced appendicitis. J Am Coll Surg, 182:403–7.
Bochicchio GV, Baquero F, Hsueh PR, et al. 2006. In vitro susceptibili-
ties of Escherichia coli isolated from patients with intra-abdominal 
infections worldwide in 2002-2004: results from SMART (Study for 
Monitoring Antimicrobial Resistance Trends). Surg Infect (Larchmt), 
7:537–45.
Bogaerts P, Naas T, Wybo I, et al. 2006. Outbreak of infection by carbap-
enem-resistant Acinetobacter baumannii producing the carbapenemase 
OXA-58 in Belgium. J Clin Microbiol, 44:4189–92.
Bogdanovich T, Esel D, Kelly LM, et al. 2005. Antistaphylococcal activ-
ity of DX-619, a new des-F(6)-quinolone, compared to those of other 
agents. Antimicrob Agents Chemother, 49:3325–33.
Bouchillon SK, Hoban DJ, Johnson BM, et al. 2005a. In vitro activ-
ity of tigecycline against 3989 Gram-negative and Gram-positive 
clinical isolates from the United States Tigecycline Evaluation and 
Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect 
Dis, 52:173–9.
Bouchillon SK, Hoban DJ, Johnson BM, et al. 2005b. In vitro evaluation 
of tigecycline and comparative agents in 3049 clinical isolates: 2001 
to 2002. Diagn Microbiol Infect Dis, 51:291–5.
Bradford PA, Weaver-Sands DT, and Petersen PJ. 2005. In vitro activity 
of tigecycline against isolates from patients enrolled in phase 3 clini-
cal trials of treatment for complicated skin and skin-structure infec-
tions and complicated intra-abdominal infections. Clin Infect Dis, 41 
(Suppl 5):S315–32.
Breedt J, Teras J, Gardovskis J, et al. 2005. Safety and effi cacy of tige-
cycline in treatment of skin and skin structure infections: results of a 
double-blind phase 3 comparison study with vancomycin-aztreonam. 
Antimicrob Agents Chemother, 49:4658–66.
Therapeutics and Clinical Risk Management 2007:3(6)1068
Townsend et al
Brismar B, Malmborg AS, Tunevall G, et al. 1995. Meropenem versus 
imipenem/cilastatin in the treatment of intra-abdominal infections. 
J Antimicrob Chemother, 35:139–48.
Brismar B, Malmborg AS, Tunevall G, et al. 1992. Piperacillin-tazobactam 
versus imipenem-cilastatin for treatment of intra-abdominal infections. 
Antimicrob Agents Chemother, 36:2766–73.
[CDCP] Centers for Disease Control and Prevention, National Health Center 
for Statistics. 1997. Vital and Health Statistics: Detailed Diagnoses 
and Procedures. National Hospital Discharge Survey, 1994. Vol. 127. 
Hyattsville, MD: U.S. Department of Health and Human Services.
[CDER] Centers for Drug Evaluation and Research. 1998. Uncomplicated 
and complicated skin and skin structure infections – Developing antimi-
crobial drugs for treatement. Guidance for Industry (online). Accessed 
5 May 2007. URL: http://www.fda.gov/cder/guidance/2566dft. pdf.
Cercenado E, Marin M, Sanchez-Martinez M, et al. 2007. In Vitro Activi-
ties of Tigecycline and Eight Other Antimicrobials against Different 
Nocardia Species Identifi ed by Molecular Methods. Antimicrob Agents 
Chemother, 51:1102–4.
Cheng NC, Hsueh PR, Liu YC, et al. 2005. In vitro activities of tigecycline, 
ertapenem, isepamicin, and other antimicrobial agents against clinically 
isolated organisms in Taiwan. Microb Drug Resist, 11:330–41.
Chopra I, Hawkey PM, Hinton M. 1992. Tetracyclines, molecular and clini-
cal aspects. J Antimicrob Chemother, 29:245–77.
Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, appli-
cations, molecular biology, and epidemiology of bacterial resistance. 
Microbiol Mol Biol Rev, 65:232–60.
Christou NV, Turgeon P, Wassef R, et al. 1996. Management of intra-
abdominal infections. The case for intraoperative cultures and 
comprehensive broad-spectrum antibiotic coverage. The Canadian 
Intra-abdominal Infection Study Group. Arch Surg, 131:1193–201.
[CLSI] Clinical and Laboratory Standards Institute [formerly National Com-
mittee for Clinical Laboratory Standards (NCCLS)] 2003a. Methods 
for dilution antimicrobial susceptibility tests for bacteria that grow 
aerobically, 6th edition. Wayne, PA.
[CLSI] Clinical and Laboratory Standards Institute [formerly National 
Committee for Clinical Laboratory Standards (NCCLS)] 2003b. Per-
formance standards for antimicrobial disk diffusion susceptibility tests, 
8th edition. Wayne, PA.
[CLSI] Clinical and Laboratory Standards Institute [formerly National 
Committee for Clinical Laboratory Standards (NCCLS)] 2004. Meth-
ods for antimicrobial susceptibility testing of anaerobic bacteria, 6th 
edition, Wayne, PA.
[CLSI] Clinical and Laboratory Standards Institute [formerly National Com-
mittee for Clinical Laboratory Standards (NCCLS)] 2005. Performance 
standards for antimicrobial susceptibility testing – 15th informational 
supplement. Wayne, PA.
Cohn SM, Lipsett PA, Buchman TG, et al. 2000. Comparison of intravenous/
oral ciprofl oxacin plus metronidazole versus piperacillin/tazobactam 
in the treatment of complicated intraabdominal infections. Ann Surg, 
232:254–62.
Colardyn F, Faulkner KL. 1996. Intravenous meropenem versus imipenem/
cilastatin in the treatment of serious bacterial infections in hospitalized 
patients. Meropenem Serious Infection Study Group. J Antimicrob 
Chemother, 38:523–37.
Condon RE, Walker AP, Sirinek KR, et al. 1995. Meropenem versus 
tobramycin plus clindamycin for treatment of intraabdominal infec-
tions: results of a prospective, randomized, double-blind clinical trial. 
Clin Infect Dis, 21:544–50.
Conte JE, Jr., Golden JA, Kelly MG, et al. 2005. Steady-state serum and 
intrapulmonary pharmacokinetics and pharmacodynamics of tigecy-
cline. Int J Antimicrob Agents, 25:523–9.
Cueto J, D’Allemagne B, Vazquez-Frias JA, et al. 2006. Morbidity of 
laparoscopic surgery for complicated appendicitis: an international 
study. Surg Endosc, 20:717–20.
Dean CR, Visalli MA, Projan SJ, et al. 2003. Effl ux-mediated resistance to 
tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob 
Agents Chemother, 47:972–8.
Dinubile MJ, Lipsky BA. 2004. Complicated infections of skin and skin 
structures: When the infection is more than skin deep. J Antimicrob 
Chemother, 53(Suppl S2):ii37–50.
Doern GV, Jones RN, Pfaller MA, et al. 1999. Bacterial pathogens isolated 
from patients with skin and soft tissue infections: frequency of occur-
rence and antimicrobial susceptibility patterns from the SENTRY 
Antimicrobial Surveillance Program (United States and Canada, 1997). 
SENTRY Study Group (North America). Diagn Microbiol Infect Dis, 
34:65–72.
Donahue PE, Smith DL, Yellin AE, et al. 1998. Trovafl oxacin in the treat-
ment of intra-abdominal infections: results of a double-blind, multi-
center comparison with imipenem/cilastatin. Trovafl oxacin Surgical 
Group. Am J Surg, 176:53S–61S.
Dougherty SH, Sirinek KR, Schauer PR, et al. 1995. Ticarcillin/clavulanate 
compared with clindamycin/gentamicin (with or without ampicillin) 
for the treatment of intra-abdominal infections in pediatric and adult 
patients. Am Surg, 61:297–303.
Eklund AE and Nord CE. 1993. A randomized multicenter trial of piper-
acillin/tazobactam versus imipenem/cilastatin in the treatment of 
severe intra-abdominal infections. Swedish Study Group. J Antimicrob 
Chemother, 31 (Suppl A):79–85.
Ellis-Grosse EJ, Babinchak T, Dartois N, et al. 2005. The effi cacy and safety 
of tigecycline in the treatment of skin and skin-structure infections: 
results of 2 double-blind phase 3 comparison studies with vancomycin-
aztreonam. Clin Infect Dis, 41 (Suppl 5):S341–53.
Ellis-Grosse E, Bradford PA, Loh E. 2005. Tigecycline in patients with 
extended-spectrum beta lactamases (ESBLs) - producing bacteria: expe-
rience from Phase III clinical trials. 43rd Infectious Diseases Society of 
America; October 6–9. San Francisco, CA: (meeting abstract).
Fabian TC, File TM, Embil JM, et al. 2005. Meropenem versus imipe-
nem-cilastatin for the treatment of hospitalized patients with com-
plicated skin and skin structure infections: results of a multicenter, 
randomized, double-blind comparative study. Surg Infect (Larchmt 
), 6:269–82.
Fass RJ, Freimer EH, McCloskey RV. 1985. Treatment of skin and soft tissue 
infections with imipenem/cilastatin. Am J Med, 78:110–12.
Fomin P, Beuran M, Gradauskas Aeal. 2005. Tigecycline is effi cacious in 
the treatment of complicated intra-abdominal infections. Int J Surg, 
3:35–47.
Fritsche TR, Sader HS, Stilwell MG, et al. 2005. Potency and spectrum 
of tigecycline tested against an international collection of bacterial 
pathogens associated with skin and soft tissue infections (2000–2004). 
Diagn Microbiol Infect Dis, 52:195–201.
Fritsche TR, Strabala PA, Sader HS, et al. 2005. Activity of tigecycline tested 
against a global collection of Enterobacteriaceae, including tetracycline-
resistant isolates. Diagn Microbiol Infect Dis, 52:209–13.
Gales AC, Jones RN, Andrade SS, et al. 2005. In vitro activity of tigecy-
cline, a new glycylcycline, tested against 1,326 clinical bacterial strains 
isolated from Latin America. Braz J Infect Dis, 9:348–56.
Garrison MW, Nuemiller JJ. 2007. In vitro activity of tigecycline against 
quinolone-resistant Streptococcus pneumoniae, methicillin-resistant 
Staphylococcus aureus and vancomycin-resistant enterococci. Int J 
Antimicrob Agents, 29:191–6.
Geroulanos SJ. 1995. Meropenem versus imipenem/cilastatin in intra-
abdominal infections requiring surgery. Meropenem Study Group. 
J Antimicrob Chemother, 36 (Suppl A):191–205.
Giordano P, Song J, Pertel P, et al. 2005. Sequential intravenous/oral 
moxifl oxacin versus intravenous piperacillin-tazobactam followed by 
oral amoxicillin-clavulanate for the treatment of complicated skin and 
skin structure infection. Int J Antimicrob Agents, 26:357–65.
Goldstein EJ, Citron DM, Merriam CV, et al. 2006. Comparative in vitro 
susceptibilities of 396 unusual anaerobic strains to tigecycline and 
eight other antimicrobial agents. Antimicrob Agents Chemother, 
50:3507–13.
Gotfried MH, Rodvold KA, Cwik M, et al. 2005. An open-label clinical 
evaluation of tigecycline concentrations in selected tissues and fl uids. 
Clin Pharmacol Ther, 77:98.
Therapeutics and Clinical Risk Management 2007:3(6) 1069
Tigecycline review
Graham DR, Lucasti C, Malafaia O, et al. 2002. Ertapenem once daily versus 
piperacillin-tazobactam 4 times per day for treatment of complicated 
skin and skin-structure infections in adults: results of a prospective, ran-
domized, double-blind multicenter study. Clin Infect Dis, 34:1460–8.
Graham DR, Talan DA, Nichols RL, et al. 2002. Once-daily, high-dose 
levofloxacin versus ticarcillin-clavulanate alone or followed by 
amoxicillin-clavulanate for complicated skin and skin-structure infec-
tions: a randomized, open-label trial. Clin Infect Dis, 35:381–9.
Grayson ML, McDonald M, Gibson K, et al. 2002. Once-daily intravenous 
cefazolin plus oral probenecid is equivalent to once-daily intravenous 
ceftriaxone plus oral placebo for the treatment of moderate-to-severe 
cellulitis in adults. Clin Infect Dis, 34:1440–8.
Hoban DJ, Bouchillon SK, Johnson BM, et al. 2005. In vitro activity of 
tigecycline against 6792 Gram-negative and Gram-positive clinical 
isolates from the global Tigecycline Evaluation and Surveillance Trial 
(TEST Program, 2004). Diagn Microbiol Infect Dis, 52:215–27.
Hoffmann M, DeMaio W, Jordan RA, et al. 2004. Metabolic disposition 
(14C) tigecycline in human volunteers following intravenous infusion. 
American Association of Pharmaceutical Scientists (AAPS) Annual 
Meeting; November 7–11. Baltimore, MD: (meeting abstract).
Huizinga WK, Warren BL, Baker LW, et al. 1995. Antibiotic monotherapy 
with meropenem in the surgical management of intra-abdominal infec-
tions. J Antimicrob Chemother, 36 (Suppl A):179–89.
Jaccard C, Troillet N, Harbarth S, et al. 1998. Prospective randomized 
comparison of imipenem-cilastatin and piperacillin-tazobactam in 
nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother, 
42:2966–72.
Kirkland KB, Briggs JP, Trivette SL, et al. 1999. The impact of surgical-site 
infections in the 1990s: attributable mortality, excess length of hospital-
ization, and extra costs. Infect Control Hosp Epidemiol, 20:725–30.
Kohler T, Michea-Hamzehpour M, Henze U, et al. 1997. Characterization 
of MexE-MexF-OprN, a positively regulated multidrug effl ux system 
of Pseudomonas aeruginosa. Mol Microbiol, 23:345–54.
Lee SY, Kuti JL, Nicolau DP. 2005. Antimicrobial management of compli-
cated skin and skin structure infections in the era of emerging resistance. 
Surg Infect, 6:283–95.
Li XZ, Nikaido H, Poole K. 1995. Role of mexA-mexB-oprM in antibiotic 
effl ux in Pseudomonas aeruginosa. Antimicrob Agents Chemother, 
39:1948–53.
Lipsky BA, Stoutenburgh U. 2005. Daptomycin for treating infected 
diabetic foot ulcers: evidence from a randomized, controlled trial 
comparing daptomycin with vancomycin or semi-synthetic penicil-
lins for complicated skin and skin-structure infections. J Antimicrob 
Chemother, 55:240–5.
Meagher AK, Ambrose PG, Grasela TH, et al. 2005. Pharmacokinetic/phar-
macodynamic profi le for tigecycline-a new glycylcycline antimicrobial 
agent. Diagn Microbiol Infect Dis, 52:165–71.
Meagher AK, Passarell JA, Cirincione BB, et al. 2007. Exposure-response 
analyses of tigecycline effi cacy in patients with complicated skin and 
skin-structure infections. Antimicrob Agents Chemother, 51:1939–45.
Mine T, Morita Y, Kataoka A, et al. 1999. Expression in Escherichia coli of 
a new multidrug effl ux pump, MexXY, from Pseudomonas aeruginosa. 
Antimicrob Agents Chemother, 43:415–17.
Moet GJ, Jones RN, Biedenbach DJ, et al. 2007. Contemporary causes of 
skin and soft tissue infections in North America, Latin America, and 
Europe: Report from the SENTRY Antimicrobial Surveillance Program 
(1998–2004). Diagn Microbiol Infect Dis, 57:7–13.
Monge JV, de Los Terreros Soler L, Diaz-Agero Perez C, et al. 2006. 
Excess length of stay attributable to surgical site infection following 
hip replacement: a nested case-control study. Infect Control Hosp 
Epidemiol, 27:1299–303.
Muralidharan G, Fruncillo RJ, Micalizzi M, et al. 2005. Effects of age and 
sex on single-dose pharmacokinetics of tigecycline in healthy subjects. 
Antimicrob Agents Chemother, 49:1656–9.
Muralidharan G, Micalizzi M, Speth J, et al. 2005. Pharmacokinetics of tige-
cycline after single and multiple doses in healthy subjects. Antimicrob 
Agents Chemother, 49:220–9.
Nichols RL. 1999. Optimal treatment of complicated skin and skin structure 
infections. J Antimicrob Chemother, 44 (Suppl A):19–23.
Nichols RL, Florman S. 2001. Clinical presentations of soft-tissue infections 
and surgical site infections. Clin Infect Dis, 33 (Suppl 2):S84–93.
Nichols RL, Graham DR, Barriere SL, et al. 1999. Treatment of hospitalized 
patients with complicated gram-positive skin and skin structure 
infections: two randomized, multicentre studies of quinupristin/
dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid 
Skin and Skin Structure Infection Group. J Antimicrob Chemother, 
44:263–73.
Ohlin B, Cederberg A, Forssell H, et al. 1999. Piperacillin/tazobactam 
compared with cefuroxime/ metronidazole in the treatment of intra-
abdominal infections. Eur J Surg, 165:875–84.
Oliva ME, Rekha A, Yellin A, et al. 2005. A multicenter trial of the effi cacy and 
safety of tigecycline versus imipenem/cilastatin in patients with compli-
cated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; 
ClinicalTrials.gov Identifi er: NCT00081744]. BMC Infect Dis, 5:88.
Olson MW, Ruzin A, Feyfant E, et al. 2006. Functional, biophysical, and 
structural bases for antibacterial activity of tigecycline. Antimicrob 
Agents Chemother, 50:2156–66.
Peleg AY, Potoski BA, Rea R, et al. 2007. Acinetobacter baumannii 
bloodstream infection while receiving tigecycline: a cautionary report. 
J Antimicrob Chemother, 59:128–31.
Petersen PJ, Bradford PA, Weiss WJ, et al. 2002. In vitro and in vivo 
activities of tigecycline (GAR-936), daptomycin, and comparative 
antimicrobial agents against glycopeptide-intermediate Staphylococcus 
aureus and other resistant gram-positive pathogens. Antimicrob Agents 
Chemother, 46:2595–601.
Poenaru D, De SM, Christou NV. 1990. Imipenem versus tobramycin 
– antianaerobe antibiotic therapy in intra-abdominal infections. Can 
J Surg, 33:415–22.
Poole K, Gotoh N, Tsujimoto H, et al. 1996. Overexpression of the mexC-
mexD-oprJ effl ux operon in nfxB-type multidrug-resistant strains of 
Pseudomonas aeruginosa. Mol Microbiol, 21:713–24.
Postier RG, Green SL, Klein SR, et al. 2004. Results of a multicenter, 
randomized, open-label effi cacy and safety study of two doses of tige-
cycline for complicated skin and skin-structure infections in hospitalized 
patients. Clin Ther, 26:704–14.
Projan SJ. 2000. Preclinical pharmacology of GAR-936, a novel glycylcy-
cline antibacterial agent. Pharmacotherapy, 20:219S–23S.
Raible D, Zimmerman JJ, Harper D, et al. 2005. Pharmacokinetics and 
Pharmacodynamics of Tigecycline and Warfarin Coadministered to 
Healthy Subjects. 45th Interscience Conference on Antimicrobial 
Agents and Chemotherapy; December 16–19. Washington, DC: 
(meeting abstract).
Rasmussen BA, Gluzman Y, Tally FP. 1994. Inhibition of protein synthe-
sis occurring on tetracycline-resistant, TetM-protected ribosomes by 
a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents 
Chemother, 38:1658–60.
Reese A and Burgess D. 2005. In vitro pharmacodynamics and post-
antibiotic effcts (PAE) of tigecycline against gram-negative bacteria. 
45th Interscience Conference on Antimicrobial Agents and Chemo-
therapy; December 16–19. Washington, DC: (meeting abstract).
Rello J. 2005. Pharmacokinetics, pharmacodynamics, safety and tolerability 
of tigecycline. J Chemother, 17 (Suppl 1):12–22.
Rennie RP, Jones RN, Mutnick AH, et al. 2003. Occurrence and antimi-
crobial susceptibility patterns of pathogens isolated from skin and soft 
tissue infections: Report from the SENTRY Antimicrobial Surveillance 
Program (United States and Canada, 2000). Diagn Microbiol Infect 
Dis, 45:287–93.
Rice LB. 2006. Challenges in identifying new antimicrobial agents effective 
for treating infections with Acinetobacter baumannii and Pseudomonas 
aeruginosa. Clin Infect Dis, 43 (Suppl 2):S100–5.
Rodriguez-Avial I, Rodriguez-Avial C, Lopez O, et al. 2006. In vitro activity 
of tigecycline (GAR-936) and other antimicrobials against tetracy-
cline- and ciprofl oxacin-resistant Campylobacter clinical isolates. Int 
J Antimicrob Agents, 27:303–6.
Therapeutics and Clinical Risk Management 2007:3(6)1070
Townsend et al
Rodvold KA, Gotfried MH, Cwik M, et al. 2006. Serum, tissue and body 
fl uid concentrations of tigecycline after a single 100 mg dose. J Anti-
microb Chemother, 58:1221–9.
Rodvold K, Gotfried M, Cwik M, et al. 2005. Tigeycline (TGC) concentration 
(Cp) in lung tissue, cerebrospinal fl uid (CSF), and bile of human subjects. 
45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 
December 16–19. Washington, DC: (meeting abstract).
Sacchidanand S, Penn RL, Embil JM, et al. 2005. Effi cacy and safety of 
tigecycline monotherapy compared with vancomycin plus aztreonam in 
patients with complicated skin and skin structure infections: Results from 
a phase 3, randomized, double-blind trial. Int J Infect Dis, 9:251–61.
Sader HS, Jones RN, Stilwell MG, et al. 2005. Tigecycline activity tested 
against 26,474 bloodstream infection isolates: a collection from 
6 continents. Diagn Microbiol Infect Dis, 52:181–6.
Saunders S, Baird-Bellaire SJ, Patat AA, et al. 2005. Pharmacokinetics 
of tigecycline (TGC) in patients with hepatic impairment. European 
Association for Clinical Pharmacology and Therapeutics; June 24–29. 
Poznan, Poland: (meeting abstract).
Scheetz MH, Reddy P, Nicolau DP, et al. 2006. Peritoneal fl uid penetration 
of tigecycline. Ann Pharmacother, 40:2064–7.
Snydman DR, Jacobus NV, McDermott LA, et al. 2007. National Survey 
on the Susceptibility of B. fragilis Group: Report and Analysis of 
Trends for 1997–2004: A US Survey. Antimicrob Agents Chemother, 
51:1649–55.
Solomkin JS, Mazuski JE, Baron EJ, et al. 2003. Guidelines for the selection 
of anti-infective agents for complicated intra-abdominal infections. Clin 
Infect Dis, 37:997–1005.
Solomkin JS, Reinhart HH, Dellinger EP, et al. 1996. Results of a ran-
domized trial comparing sequential intravenous/oral treatment with 
ciprofl oxacin plus metronidazole to imipenem/cilastatin for intra-
abdominal infections. The Intra-Abdominal Infection Study Group. 
Ann Surg, 223:303–15.
Solomkin JS, Wilson SE, Christou NV, et al. 2001. Results of a clinical 
trial of clinafl oxacin versus imipenem/cilastatin for intraabdominal 
infections. Ann Surg, 233:79–87.
Solomkin JS, Yellin AE, Rotstein OD, et al 2003. Ertapenem versus piper-
acillin/tazobactam in the treatment of complicated intra-abdominal 
infections: results of a double-blind, randomized comparative phase 
III trial. Ann Surg, 237:235–45.
Sorlozano A, Gutierrez J, Salmeron A, et al. 2006. Activity of tigecycline 
against clinical isolates of Staphylococcus aureus and extended-spec-
trum beta-lactamase-producing Escherichia coli in Granada, Spain. Int 
J Antimicrob Agents, 28:532–6.
Speer BS, Shoemaker NB, Salyers AA. 1992. Bacterial resistance to tetra-
cycline: mechanisms, transfer, and clinical signifi cance. Clin Microbiol 
Rev, 5:387–99.
Stevens DL, Bisno AL, Chambers HF, et al. 2005. Practice guidelines for 
the diagnosis and management of skin and soft-tissue infections. Clin 
Infect Dis, 41:1373–406.
Stevens DL, Smith LG, Bruss JB, et al. 2000. Randomized comparison of 
linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment 
of complicated skin and soft tissue infections. Antimicrob Agents 
Chemother, 44:3408–13.
Sturkenboom MC, Goettsch WG, Picelli G, et al. 2005. Inappropriate initial 
treatment of secondary intra-abdominal infections leads to increased risk 
of clinical failure and costs. Br J Clin Pharmacol, 60:438–43.
Sun HK, Ong CT, Umer A, et al. 2005. Pharmacokinetic profile of 
tigecycline in serum and skin blister fl uid of healthy subjects after 
multiple intravenous administrations. Antimicrob Agents Chemother, 
49:1629–32.
Taccone FS, Rodriguez-Villalobos H, De BD, et al. 2006. Successful treat-
ment of septic shock due to pan-resistant Acinetobacter baumannii 
using combined antimicrobial therapy including tigecycline. Eur J Clin 
Microbiol Infect Dis, 25:257–60.
Talan DA, Summanen PH, Finegold SM. 2000. Ampicillin/sulbactam and 
cefoxitin in the treatment of cutaneous and other soft-tissue abscesses 
in patients with or without histories of injection drug abuse. Clin Infect 
Dis, 31:464–71.
Tally FT, Ellestad GA, Testa RT. 1995. Glycylcyclines: a new generation 
of tetracyclines. J Antimicrob Chemother, 35:449–52.
Tan JS, Wishnow RM, Talan DA, et al. 1993. Treatment of hospitalized 
patients with complicated skin and skin structure infections: double-
blind, randomized, multicenter study of piperacillin-tazobactam versus 
ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin 
Structure Study Group. Antimicrob Agents Chemother, 37:1580–6.
[EUCAST Steering Committee] The European Committee on Antimicrobial 
Susceptility Testing (EUCAST) Steering Committee. 2006. EUCAST 
technical note on tigecycline. Clin Microbiol Infect, 12:1147–9.
Tombs NL. 1999. Tissue distribution of GAR-936, a broad spectrum 
antibiotic in male rats. 39th Interscience Conference on Antimicrobial 
Agents and Chemotherapy; September 26–29. San Francisco, CA: 
(meeting abstract).
Townsend ML, Pound MW, Drew RH. 2006. Tigecycline: a new glycylcy-
cline antimicrobial. Int J Clin Pract, 60:1662–72.
Troy SM, Muralidharan G, Micalizzi M, et al. 2003. The effects of renal 
disease on the pharmacokinetics of tigecycline (GAR-936). 43rd 
Interscience Conference on Antimicrobial Agents and Chemotherapy; 
September 14–17. Chicago, IL: (meeting abstract).
van Ogtrop ML, Andes D, Stamstad TJ, et al. 2000. In vivo pharmacody-
namic activities of two glycylcyclines (GAR-936 and WAY 152,288) 
against various gram-positive and gram-negative bacteria. Antimicrob 
Agents Chemother, 44:943–9.
Van Wart SA, Owen JS, Ludwig EA, et al. 2006. Population pharmaco-
kinetics of tigecycline in patients with complicated intra-abdominal 
or skin and skin structure infections. Antimicrob Agents Chemother, 
50:3701–7.
Vegas AA, Jodra VM, Garcia ML. 1993. Nosocomial infection in surgery 
wards: a controlled study of increased duration of hospital stays and 
direct cost of hospitalization. Eur J Epidemiol, 9:504–10.
Waites KB, Duffy LB, Dowzicky MJ. 2006. Antimicrobial susceptibility 
among pathogens collected from hospitalized patients in the United 
States and in vitro activity of tigecycline, a new glycylcycline antimi-
crobial. Antimicrob Agents Chemother, 50:3479–84.
Walker AP, Nichols RL, Wilson RF, et al. 1993. Effi cacy of a beta-lactamase 
inhibitor combination for serious intra-abdominal infections. Ann Surg, 
217:115–21.
Westbrock-Wadman S, Sherman DR, Hickey MJ, et al. 1999. Charac-
terization of a Pseudomonas aeruginosa effl ux pump contributing 
to aminoglycoside impermeability. Antimicrob Agents Chemother, 
43:2975–83.
Wyeth Pharmaceuticals. 2007a. Data on File (CSR-44355). Philadelphia, PA.
Wyeth Pharmaceuticals. 2007b. Tygacil (package insert). Philadelphia, PA.
Zhanel GG, Homenuik K, Nichol K, et al. 2004. The glycylcyclines: a 
comparative review with the tetracyclines. Drugs, 64:63–88.
Zimmerman JJ, Harper D, Matschke K, et al. 2004. Tigecycline and digoxin 
co-administered to healthy men. 44th Interscience Conference on 
Antimicrobial Agents and Chemotherapy; October 30–November 2. 
Washington, DC: (meeting abstract).
Zimmerman JJ, Harper DM, Matschke K, et al. 2007. Absence of an interac-
tion between tigecycline and digoxin in healthy men. Pharmacotherapy, 
27:835–44.
